Adaptation of Two Primary Human Immunodeficiency Virus Type 1 Isolates to Growth in Transformed T Cell Lines Correlates with Alterations in the Responses of Their Envelope Glycoproteins to Soluble CD4

AIDS Research and Human Retroviruses

Volumn 9, Issue 6, 1993, Pages 529-539

  Moore, John P ^a   Burkly, Linda C ^b   Connor, Ruth I ^a   Cao, Yunzhen ^a   Tizard, Richard ^b   ho, David D ^a   Fisher, Richard A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN;

ADAPTATION; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; ENVELOPE GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; SEQUENCE HOMOLOGY; VIROGENESIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ADAPTATION, BIOLOGICAL; AMINO ACID SEQUENCE; ANTIGENS, CD4; BASE SEQUENCE; CELL LINE, TRANSFORMED; COLD; COMPARATIVE STUDY; GENE PRODUCTS, ENV; HEAT; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMAN; MACROPHAGES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES; VARIATION (GENETICS); VIRUS REPLICATION;

EID: 0027168953     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1993.9.529     Document Type: Article

References (73)

1. Åsjö B., Morfeldt-Månson L., Albert LJ., Biberfeld G., Karlson A., Lidman K., and Fenyö EM.: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986; ii: 660–662.
2. Cheng-Mayer C., Seto D. Tateno M., and Levy JA.: Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240: 80–82.
3. Evans LA., McHugh TM., Stites DP., and Levy JA.: Differential ability of human immunodeficiency virus isolates to productively inject human cells. J Immunol 1987; 138: 3415–3418.
4. Fenyö EM., Morfeldt-Månson L., Chiodi F., Lind B., von Gegerfelt A., Albert J., Olausson E., and Åsjö B.: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988; 62: 4414–4419.
5. Groenink M., Fouchier RAM.: de Goede REY.: de Wolf F., Gruters RA., Cuypers HTM., Huisman HG., and Tersmette M.: Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol 1991; 65: 1968–1975.
6. Tersmette M., de Goede REY., Al BJM., Winkel IN., Gruters RA., Cuypers HT., Huisman HG., and Miedema F.: Differential syncytium-inducing capacity ofhuman immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988; 62: 2026–2032.
7. Fenyö EM., Albert J., and Åsjö B.: Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989; 3(Suppl. 1):S5–S12.
8. Miedema F., Tersmette M., and van Lier RAW.: AIDS pathogenesis: a dynamic interaction between HIV and the immune system. Immunol Today 1990; 11: 293–297.
9. Schuitemaker H., Koot M., Kootstra NA., Dergksen MW., de Goede REY., van Steenwijk RP., Lange JMA., Eeftink Schattenkerk JKM., Miedema F., and Tersmette M.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 1992; 66: 1354–1360.
10. Schuitemaker H., Kootstra NA., de Goede REY., de Wolf F., Miedema F., and Tersmette M.: Monocytotropic human immunode ficiency virus type 1 (HIV-I) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991; 65: 356–363.
11. Tersmette M., Gruters RA., de Wolf F., de Goede REY., Lange JMA., Schellekens PTA., Coutinho RA., Huisman JG., Goudsmit J., and Miedema F.: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunideficiency syndrome obtained from studies on a panel of sequential HIV isolates. J Virol 1989; 63: 2118–2125.
12. Fernandez-Larsson R., Srivastava KK., Lu S., and Robinson HL.: Replication of patient isolates of human immunodeficiency virus type 1 in cells: a spectrum of rates and efficiencies of entry. Proc Nati Acad Sci USA 1992; 89: 2223–2226.
13. Lu S., Putney SD., and Robinson HL.: Human immunodeficiency virus type 1 entry into cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. J Virol 1992; 66: 2547–2550.
14. Srivastava KK., Fernandez-Larsson R., Zinkus DM., and Robinson HL.: Human immunodeficiency virus type I NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness. J Virol 1991; 65: 3900–3902.
15. Cheng-Mayer C., Quiroga M., Tung JW., Dina D., and Levy J.: Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity and CD4 antigen modulation. J Virol 1990; 64: 4390–4398.
16. Cheng-Mayer C., Seto D., and Levy JA.: Altered host range of HIV-1 after passage through various human cell types. Virology 1991; 181: 288–294.
17. Cheng-Mayer C., Shioda T., and Levy JA.: Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in Tat and gp 120. J Virol 1991; 65: 6931–6941.
18. Hwang SS., Boyle TJ., Lyerly K., and Cullen BR.: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253: 1–74.
19. Liu Z-Q., Wood C., Levy JA., and Cheng-Mayer C.: The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol 1990; 64: 6148–6153.
20. O'Brien WA., Koyanagi Y., Namazie A., Zhao J-Q., Diagne A., Idler K., Zack JA., and Chen ISY.: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gpi20 outside the CD4-binding domain. Nature (London) 1990; 348: 69–73.
21. Shioda T., Levy JA., and Cheng-Mayer C.: Macrophage and cell-line tropisms of HIV-1 are determined by specific regions of the envelope gpi20 gene. Nature (London) 1991; 349: 167–169.
22. Takeuchi Y., Akutsu M., Murayama K., Shimizu N., and Hoshino H.: Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol 1991; 65: 1710–1718.
23. Westervelt P., Gendelman H., and Ratner L.: Identification of a determinant within the human immunodeficiency virus type 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Nati Acad Sci USA 1991; 88: 3097–3101.
24. York-Higgins D., Cheng-Mayer C., Bauer D., Levy JA., and Dina D.: Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol 1990; 64: 4016–4020.
25. Cheng-Mayer C.: Biological and molecular features of HIV-1 related to tissue tropism. AIDS 1990; 4(Suppl. 1):S49–S56.
26. Moore JP. and Nara PL.: The role of the V3 loop of gpi20 in HIV infection. AIDS 1991; 5(Suppl. 2):S21–S33.
27. de Jong JJ., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., and de Ronde A.: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992; 66: 757–765.
28. Fouchier RAM., Groenink M., Kootstra NA., Tersmette M., Huisman HG., Miedema F., and Schuitemaker H.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency-virus type 1 gpl20 molecule. J Virol 1992; 66: 3183–3187.
29. de Jong JJ., de Ronde A., Keulen W., Tersmette M., and Goudsmit J.: Minimal requirement for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducung phenotype: analysis by single amino acid substitution. J Virol 1992; 66: 6777–6780.
30. Groenink M., Andeweg AC., Fouchier RAM., Broersen S., van der\ Jagt RCM., Schuitemaker H., de Goede REY., Bosch ML., Huisman HG., and Tersmette M.: Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 1992; 66: 6175–6180.
31. Daar ES., Li XL., Moudgil T., and Ho DD.: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Nati Acad Sci USA 1990; 87: 6574–6578.
32. Gomatos PJ., Stamatos NM., Gendelman HE., Fowler A., Hoover DL., Kalter DC., Burke DS., Tramont EC., and Meltzer MS.: Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and cells. J Immunol 1990; 144: 4183–4188.
33. Ashkenazi A., Smith DH., Marsters SA., Riddle L., Gregory TJ., Ho DD., and Capon DJ.: Resistance of primary HIV-1 isolates to soluble CD4 is independent of CD4-gpl20 binding affinity. Proc Nati Acad Sci USA 1991; 88: 7056–7060.
34. Brighty DW., Rosenberg M., Chen ISY., and Ivey-Hoyle M.: Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Nati Acad Sci USA 1991; 88: 7802–7805.
35. Moore JP., McKeating JA., Huang Y., Ashkenazi A., and Ho DD.: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gpi20 retention from sCD4-sensitive isolates. J Virol 1992; 66: 235–243.
36. Turner S., Tizard R., DeMarinis J., Pepinsky RB., Zullo J., Schooley R., and Fisher R.: Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp 120. Proc Nati Acad Sci USA 1992; 89: 1335–1339.
37. O'Brien WA., Chen ISY., Ho DD., and Daar ES.: Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol 1992; 66: 3125–3130.
38. Hwang SS., Boyle RJ., Lyerly K., and Cullen BR.: Identification of envelope V3 loop as the major determinant of CD4 neutralisation sensitivity of HIV-1. Science 1992; 257: 535–537.
39. Moore JP., McKeating JA., Weiss RA., and Sattentau QJ.: Dissociation of gp 120 from HIV-1 virions induced by soluble CD4. Science 1990; 250: 1139–1142.
40. Burkly LC., Olson D., Shapiro R., Winkler G., Rosa JJ., Thomas DW., Williams C., and Chisholm P.: Inhibition of HIV entry by a CD4 domain 2 specific monoclonal antibody: dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992; 149: 1779–1787.
41. + cells. J Virol 1992; 66: 4784–4793.
42. Fisher RA., Bertonis JM., Meier W., Johnson VA., Costopoulos DS., Liu T., Tizard R., Walker BD., Hirsch MS., Schooley RT., and Flavell RA.: HIV infection is blocked in vitro by recombinant soluble CD4. Nature (London) 1988; 331: 76–78.
43. Moore JP., McKeating JA., Norton WA., and Sattentau QJ.: Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gpi20 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol 1991; 65: 1133–1140.
44. Moore JP. and Klasse PJ.: Thermodynamics and kinetic analysis of sCD4 binding to HIV-1 virions and of gpl20 dissociation. AIDS Res Hum Retroviruses 1992; 8: 443–450.
45. + cells: implications for inhibition of virus infection and initial steps of virus entry into cells. Virology 1992; 187: 398–406.
46. Schulz TF., Jameson BA., Lopalco L., Siccardi AG., Weiss RA., and Moore JP.: Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res Hum Retroviruses 1992; 8: 1571–1580.
47. Dimitrov DS., Hillman K., Manischewitz J., Blumenthal R., and Golding H.: Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1992; 66: 132–138.
48. Klasse PJ. and Moore JP.: Kinetics of the HIV-CD4 interaction and virus-cell fusion. AIDS 1992; 6: 325–327.
49. Moebius U., Clayton LK., Abraham S., Harrison SC., and Reinherz EL.: The human immunodeficiency virus gpi20 binding site on CD4: delineation by quantitative equilibrium and kinetic studies of mutants in conjunction with a high-resolution CD4 atomic structure. J Exp Med 1992; 176: 507–517.
50. Layne SP., Spouge JL., and Dembo M.: Quantifying the infectivity of human immunodeficiency virus. Proc Nati Acad Sci USA 1989; 86: 4644–4648.
51. Thali M., Olshevsky U., Furman C., Gabuzda D., Li J., and Sodroski J.: Effects of changes in gpl20-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol 1991; 65: 5007–5012.
52. Moore JP. and Ho DD.: Antibodies to discontinuous or conformationally-sensitive epitopes on the gpi20 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993; 67: 863–875.
53. Allan JS.: Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 1991; 252: 1322–1323.
54. Allan JS., Strauss J., and Buck DW.: Enhancement of SIV infection with soluble receptor molecules. Science 1990; 247: 1084–1088.
55. + cells from virus binding. J Exp Med 1990; 172: 1233–1242.
56. Kowalski ML., Potz J., Basiripour L., Dorfman T., Goh WC., Terwilliger E., Dayton A., Rosen C., Haseltine W., and Sodroski J.: Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 1987; 237: 1351–1355.
57. Moore JP., McKeating JA., Weiss RA., Clapham PR., and Sattentau QJ.: Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 1991; 252: 1322–1323.
58. Sattentau QJ. and Moore JP.: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991; 174: 407–415.
59. Thali M., Furman C., Helseth E., Repke H., and Sodroski J.: Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992; 66: 5516–5524.
60. Layne SP., Merges MJ., Spouge JL., Dembo M., and Nara PL.: Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J Virol 1991; 65: 3293–3300.
61. Gabuzda DH., Lever A., Terwilliger E., and Sodroski J.: Effects of deletions in the cytoplasmic domain on biologic functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 1992; 66: 3306–3315.
62. Gidwitz S., Polo JM., Davis NL., and Johnston RE.: Differences in virion stability among Sindbis virus pathogenesis mutants. Virus Res 1988; 10: 225–240.
63. Glasgow GM., Sheahan BJ., Atkins GJ., Wahlberg JM., Salminen A., and Liljeström P.: Two mutations in the envelope glycoprotein E2 of Semliki Forest virus affecting the maturation and entry patterns of the virus alter pathogenicity for mice. Virology 1991; 185: 741–748.
64. Hoxie JA., Brass LF., Pletcher CH., Haggarty BS., Colloran R., and Hahn BH.: Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4. J Virol 1991; 65: 5096–5101.
65. Looney DJ., Hayashi S., Nicklas M., Redfield RR., Broder S., Wong-Staal F., and Mitsuya H.: Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr 1990; 3: 649–657.
66. Brody A. and Hunter E.: Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol 1992; 66: 3466–3475.
67. Wilson C., Reitz MS., Aldrich K., Klasse PJ., Blomberg J., Gallo RC., and Robert-Guroff M.: The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol 1990; 64: 3240–3248.
68. Nara PL., Garrity RR., and Goudsmit J.: Neutralization of HIV-1: a paradox of humoral proportions. FASEB J 1991; 5: 2437–2455.
69. Willey RL., Ross EK., Buckler-White AJ., Theodore TS., and Martin MA.: Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gpi 20. J Virol 1989; 63: 3595–3600.
70. Westervelt P., Trowbridge DB., Epstein LG., Blumberg BM., Li Y., Hahn BH., Shaw GM., Price RW., and Ratner L.: Macrophage tropism determinants of human immunodeficiency virus type 2 in vivo. J Virol 1992; 66: 2577–2582.
71. Fujita K., Silver J., and Peden K.: Changes in both gpl20 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type I. J Virol 1992; 66: 4445–4451.
72. Leonard CK., Spellman MW., Riddle L., Harris RJ., Thomas JN., and Gregory TJ.: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gpi20) expressed in Chinese Hamster ovary cells. J Biol Chem 1990; 265: 10373–10382.
73. Gallaher WR., Ball JM., Garry RF., Griffin MC., and Montelaro RC.: A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989; 5: 431–440.